Vaxxinity has announced that its Phase 1 clinical trial of the investigational vaccine UB-312 for Parkinson's disease (PD) has met primary objectives. The vaccine was immunogenic in patients with early PD and generally safe and well-tolerated, demonstrating potential as a candidate for the prevention or modification of PD. UB-312 is an investigational synthetic peptide vaccine that targets toxic..
Tvardi Therapeutics has announced that the first patients have been dosed in each arm of its REVERT LIVER CANCER trial, which is evaluating TTI-101 as monotherapy and in combination with standard of care therapy for liver cancer. The trial is designed to evaluate TTI-101 across multiple lines of therapy and is currently enrolling HCC patients at top US cancer research institutes. Liver cancer is..
Propanc Biopharma, a biopharmaceutical company focused on developing novel cancer treatments for patients with recurring and metastatic cancer, has announced that it is entering into a transformational stage as it prepares to file a Form 10-K annual report. The report will include recent developments and forecast for 2023/24. Propanc's lead product candidate PRP targets and eradicates cancer ste..
Oncolytics Biotech has announced that its drug, pelareorep, has been selected for inclusion in Precision PromiseSM, a Phase 3 clinical trial designed to evaluate the drug in combination with checkpoint inhibitors and chemotherapeutic agents gemcitabine and nab-paclitaxel. The trial is expected to support approval of the studied combination as a treatment for first-line metastatic pancreatic duct..
TransCode Therapeutics has published new data supporting the use of TTX-MC138 for the treatment of metastatic breast cancer. The lead therapeutic candidate, designed to inhibit microRNA-10b, has been shown to impair the capacity of cancer stem cells to create new tumors and become metastatic in breast cancer cells. Inhibiting these cells could improve outcomes in patients with recurrent and resi..
